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The improper activation of the Abl tyrosine kinase results in chronic myeloid leukemia (CML). The recognition of an
inactive conformation of Abl, in which a catalytically important Asp-Phe-Gly (DFG) motif is flipped by approximately
1808 with respect to the active conformation, underlies the specificity of the cancer drug imatinib, which is used to
treat CML. The DFG motif is not flipped in crystal structures of inactive forms of the closely related Src kinases, and
imatinib does not inhibit c-Src. We present a structure of the kinase domain of Abl, determined in complex with an
ATP–peptide conjugate, in which the protein adopts an inactive conformation that resembles closely that of the Src
kinases. An interesting aspect of the Src-like inactive structure, suggested by molecular dynamics simulations and
additional crystal structures, is the presence of features that might facilitate the flip of the DFG motif by providing
room for the phenylalanine to move and by coordinating the aspartate side chain as it leaves the active site. One class
of mutations in BCR–Abl that confers resistance to imatinib appears more likely to destabilize the inactive Src-like
conformation than the active or imatinib-bound conformations. Our results suggest that interconversion between
distinctly different inactive conformations is a characteristic feature of the Abl kinase domain.
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Introduction
The evolution of specialized regulatory mechanisms in
protein kinases is reflected in the range of distinct inactive
conformations of kinase domains from different subfamilies
[1,2]. This array of alternative inactive states provides
opportunities for the development of selective kinase
inhibitors, as exemplified by the success of imatinib (Gleevec,
Glivec; Novartis) in blocking the activity of BCR–Abl [3] and
its efficacy in the treatment of chronic myelogenous
leukemia. BCR–Abl is a constitutively activated form of the
nonreceptor tyrosine kinase c-Abl. The kinase domains of
BCR–Abl and c-Abl are identical in sequence, and we shall
use ‘‘Abl’’ to refer jointly to BCR–Abl and c-Abl in this paper.
Structural differences between the inactive conformations of
tyrosine kinase domains of Abl and its close relative c-Src
suggest possible explanations for why imatinib can inhibit the
kinase domain of Abl but not that of c-Src [3,4].
The structural analysis of small molecule inhibitors bound
to p38-Map kinase [5] and imatinib bound to Abl [4] have
illustrated how the recognition of inactive conformations of
kinase domains can lead to specificity in kinase inhibition.
These and subsequent studies have led to the concept that the
inactive states of kinases, which have varied structures
because they are not constrained by the necessity of
catalyzing the phospho-transfer reaction, can provide addi-
tional opportunities for specificity in inhibitor interactions
with the highly conserved kinase active sites. In this paper we
present the results of new crystallographic studies on the
kinase domain of Abl, which reveal a hitherto unappreciated
degree of conformational variability in this kinase domain.
c-Src and c-Abl are closely related nonreceptor tyrosine
kinases whose catalytic activities are controlled by their Src
homology domains SH2 and SH3 [6]. In structures of inactive
Src kinases, the SH2 and SH3 domains stabilize a conforma-
tion of the kinase domain in which a prominent a-helix (helix
aC) in the N-terminal lobe (N-lobe) is swung out of the active
site, breaking an ion pair between two conserved residues,
Glu 310 in helix aC and Lys 295 in the b-sheet of the N-lobe
[7,8]. The N-lobe closes down over the C-terminal lobe (C-
lobe) of the kinase domain. A centrally located ‘‘activation
loop’’ also changes structure, switching from an open and
extended conformation in the active state to a more closed
conformation in the inactive state. A conserved and catalyti-
cally crucial Asp-Phe-Gly (DFG) motif [2] is located at the base
of the activation loop. The portion of the activation loop that
Academic Editor: Tony Pawson, Samuel Lunenfeld Research Institute, Canada
Received November 8, 2005; Accepted March 3, 2006; Published May 2, 2006
DOI: 10.1371/journal.pbio.0040144
Copyright:  2006 Levinson et al. This is an open-access article distributed under
the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author
and source are credited.
Abbreviations: C-lobe, C-terminal lobe; DFG, Asp-Phe-Gly; HRD, His-Arg-Asp;
H396P, His 396 Pro; N-lobe, N-terminal lobe; r.m.s., root mean square
* To whom correspondence should be addressed. E-mail: kuriyan@berkeley.edu
[ These authors contributed equally to this work.
¤ Current address: Department of Biological Chemistry and the Bioinformatics
Program, University of Michigan Medical School, Ann Arbor, Michigan, United
States of America
PLoS Biology | www.plosbiology.org May 2006 | Volume 4 | Issue 5 | e1440753
PLoS BIOLOGY
PLoS Biology | www.plosbiology.org May 2006 | Volume 4 | Issue 5 | e1440754
A Src-Like Conformation of Abl
immediately follows the DFG motif forms a helical turn that
packs against the outwardly displaced helix aC (Figure 1). The
rest of the activation loop is flexible and is not always
visualized in the same conformation in inactive Src kinases.
We refer to the mode of inactivation used by the Src family
kinases as ‘‘aC-GluOut,’’because the breakingof the conserved
ion pair and the outward movement of helix aC are distinctive
features of this conformation. The Src-like inactive conforma-
tion is illustrated in Figure 1B and is contrasted to the
conformation of an active kinase domain shown in Figure 1C.
The conformation of the active kinase domain is usually
stabilized by phosphorylation of the activation loop.
The SH2 and SH3 domains of inactive c-Abl dock onto the
kinase domain in a slightly different manner than in the
inactive Src kinases, and this difference is correlated with
differences in the structures of the inactive kinase domains of
Abl and Src [9,10]. Helix aC is rotated inward in inactive c-Abl,
and the conserved ion pair between Lys 271 and Glu 286 (Abl
1a numbering) is formed (‘‘aC-Glu In’’ in contrast to ‘‘aC-Glu
Out’’ in c-Src). The orientation of the two lobes of the kinase
domain of inactive c-Abl is essentially the same as in active
kinases and is more open than inactive c-Src. The critical
conformational change in inactive c-Abl with respect to the
active form involves an approximately 1808 rotation in the
backbone torsion angle u of Asp 381 of the DFG motif, which
removes the side chain of Asp 381 from the site of Mg2þ
coordination (‘‘DFG-Asp Out,’’ in contrast to the conforma-
tion in active kinases, which we call ‘‘DFG-Asp In’’). The region
of the activation loop that is C-terminal to the DFG motif
blocks substrate binding by mimicking the conformation of a
kinase substrate peptide [4,11,12]. Because the activation loop
is clearly flexible, we view the DFG flip as the defining
inactivating transition of the Abl kinase domain (Figure 1A).
The flipped conformation of the DFG motif (DFG-Asp Out)
is required for high-affinity imatinib binding, and the Src
family inactive conformation (aC-Glu Out and DFG-Asp In) is
not bound with high affinity by imatinib. The crystal
structures of the tyrosine kinase domains of the insulin
receptor, c-Kit (with and without imatinib bound), Flt3, Csk,
and the Ser/Thr kinases Raf and p38, have revealed that many
different kinases, with no specific relationship to Abl, can
adopt conformations in which the DFG motif is flipped [12–
17]. Kinase inhibitors that recognize the flipped DFG
conformation are promising drug development leads. Imati-
nib itself is already being used successfully in the treatment of
gastrointestinal stromal tumors and myeloproliferative dis-
eases caused by the activation of the tyrosine kinases c-Kit
and PDGFR [18–20].
The key attributes of the inactive conformation of the Src
kinases are also seen in the cyclin-free inactive form of CDK2
[21], the kinase domain of the epidermal growth factor
receptor [22], and the kinase domain of GCN2, a protein
kinase involved in the cellular stress response [23]. Thus, the
inactive conformations of c-Abl and c-Src appear to be
representative of two disparate groups of kinases that, in
their inactive forms, either have the DFG motif flipped
(DFG-Asp Out) or have helix aC rotated out of the active site
(aC-Glu Out).
The work presented here concerns structures of the
isolated kinase domain of Abl, determined in the absence of
the SH2 and SH3 domains or other regulatory domains. The
presence of these additional domains significantly influences
the catalytic properties of full-length c-Abl and BCR–Abl.
The BCR segment of BCR–Abl, for example, induces
oligomerization of the protein, which facilitates the trans-
autophosphorylation of the Abl kinase domain [24]. Auto-
phosphorylation, in turn, is believed to stabilize the kinase
domain in the active conformation. Nevertheless, under-
standing the conformational landscape of the isolated and
unphosphorylated kinase domain is of interest because the
presence of additional domains, or posttranslational mod-
ifications, such as phosphorylation, is likely to modulate the
degree to which conformations that are accessible to the
isolated kinase domain are populated.
In the first part of this paper we present crystal structures
of the Abl kinase domain bound to substrate-mimicking ATP
analog–peptide conjugates that represent four distinct con-
formations of the unphosphorylated kinase domain. Un-
expectedly, one of these structures of the Abl kinase domain
has a striking similarity to the conformation of inactive Src
kinases (DFG-Asp In, aC-Glu Out). This is the first time that
the same protein has been seen to adopt both the DFG-Asp
Out and the aC-Glu Out inactive conformations. The other
structures include active and various inactive conformations
that suggest how the kinase domain might convert between
the aC-Glu In and aC-Glu Out conformations. In the second
part of the paper we present a speculation, based on
computer simulations and the new crystal structures, regard-
ing a potential role for the Src-like inactive structure in
facilitating the DFG flip. In the last part of the paper we
identify a class of imatinib resistance mutations in the BCR–
Abl kinase domain whose locations in the structure suggest
that destabilization of the Src-like inactive structure might
impact the binding of imatinib to Abl.
Results/Discussion
Crystal Structures
In this paper we discuss five distinct conformations of the
kinase domain of Abl, based on four new crystal structures as
well as the previously published structure of the Abl:imatinib
Figure 1. Distinct States of the c-Abl and c-Src Kinase Domains
Three key kinase domain conformations considered at length in the text are shown in (A–C). At the top, a schematic representation of each state and an
enlarged schematic are shown, detailing the conformations of the DFG motif (red) and helix aC (blue). Below the schematics the crystal structure of
each conformation is shown. The activation loop is colored red, helix aC blue, and the catalytic loop orange.
(A) The conformation of inactive c-Abl, bound to imatinib (molecule A).
(B) The conformation of the inactive Src family kinases. This conformation is now seen in Abl as well (molecule B, structure 1). Both the c-Src and Abl
numbering are indicated.
(C) Active Abl (molecule C, structure 2).
(D) In cells the active conformation of Abl undergoes rapid autophosphorylation that is expected to trap the protein in the active conformation
(indicated as C*). Similarly, imatinib only binds to Abl when the kinase domain adopts conformation A and forms a stable complex with the protein (A*).
The interconversion between the different states of Abl is shown in the context of this competition.
DOI: 10.1371/journal.pbio.0040144.g001
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complex (Table 1). The protein samples used for crystalliza-
tion consisted of the isolated kinase domain that was not
phosphorylated on the activation loop, and we assume that
increased flexibility of the protein under these conditions is
responsible for the isolation of multiple distinct conforma-
tions. The crystallographic data and refinement statistics are
noted in Table S1.
The first of these conformations is that of the kinase
domain bound to imatinib, determined previously [9], and is
denoted molecule A (Table 1 and Figure 1A). The remaining
conformations are derived from three different crystal forms
obtained in the presence of ATP analog–peptide conjugates
[25]. These bisubstrate analogs inhibit the activity of the Abl
kinase domain with Ki values of approximately 1 lM (see
Protocol S1 for a description of the kinetic characterization).
In the first of our new structures (Table 1, molecule B; and
Figure 1B), the kinase domain of Abl assumes a conformation
that is strikingly similar to that of the inactive Src kinases
(DFG-Asp In/aC-Glu Out). We obtained two additional crystal
forms, representing three different conformations of the
kinase domain, using a construct of Abl that contains a
patient-derived imatinib resistance mutation in the activa-
tion loop, His 396 Pro (H396P).
One crystal form of the H396P mutant has Abl in an active
conformation (Table 1, molecule C). These crystals diffracted
X-rays weakly, and the structure was solved to 3.1 A˚
resolution. Molecule C is shown in Figure 1C and is very
similar to the crystal structure of the kinase domain of Abl
H396P bound to the small molecule inhibitor VX-680 [26],
which has provided a high-resolution (2.0 A˚) model of the
active conformation of the Abl kinase domain [27]. The
isolation of the same conformation in the presence of an ATP
analog–peptide conjugate demonstrates that these substrate
analogs are compatible with the active form of the kinase
domain.
The other crystal form of the H396P mutant has two
molecules in the asymmetric unit that are in different
conformations. The first of these molecules (molecule D) is
in an inactive conformation with a flipped DFG motif (DFG-
Asp Out/aC-Glu In) despite the presence of the ATP analog in
the nucleotide-binding site. Previously, DFG-Asp Out con-
formations of Abl have only been seen in the presence of
high-affinity kinase inhibitors such as imatinib and
PD166326. The appearance of the DFG-Asp Out conforma-
tion in the presence of a nucleotide analog shows that this
conformation is an accessible state of the kinase domain of
Abl and is not induced only by the binding of high-affinity
kinase inhibitors. Because of the similarity to previously
reported structures of Abl [9,28], we do not consider this
conformation further.
The second molecule (molecule E) in this crystal form is in
an intermediate conformation, with helix aC partially swung
out of the active site and with disruption of the conserved ion
pair between Glu 286 and Lys 271 (DFG-Asp Out/aC-Glu
Out). The same crystal form was also obtained with the small
molecule inhibitor PD166326 [29]. Crystals obtained with
PD166326 are isomorphous to those obtained with the
peptide–ATP conjugate, but diffract X-rays to higher
resolution (see Materials and Methods). The resulting models
are very similar, with differences limited to local changes that
are a consequence of the different ligands. The conformation
of Abl represented by molecules E and G suggests a
mechanism by which Abl can interconvert between aC-Glu
In and aC-Glu Out conformations.
A Structure of the Abl Kinase Domain That Resembles
Inactive Src Kinases
The structure of molecule B is shown in Figure 2A. The
peptide portion of the substrate analog is bound to the
activation loop and the C-lobe of the kinase domain
essentially as seen previously in crystal structures of the
insulin receptor kinase domain [11,30], except that the
activation loop and the bound peptide have rotated outward
as a unit with respect to the center of the kinase domain
(Figure 2A and Figure S1).
The conformation of molecule B is dramatically different
from all other structures of Abl determined to date, all of
which adopt the aC-Glu In conformation. In molecule B,
helix aC is swung out of the active site (aC-Glu Out), a
conformational change corresponding to an outward rota-
tion of 348 about the helix axis and a 318 pivot of the helix
axis with respect to the conformation of helix aC in active
Abl (Table 1, molecule C; and Figure 1C). As a result of the
movement of the helix, the conserved salt bridge between Lys
271 and Glu 286 is broken. Both of these charged residues
form new ion-pairing interactions.
The side chain of Glu 286, which is surface-exposed
because of the rotation of helix aC, forms an ion pair with
Arg 386 within the activation loop (Figure 1A). The side chain
of Lys 271 forms a salt bridge with the side chain of Asp 381
of the DFG motif in molecule B. As a consequence, the side
chain of Asp 381 is moved relative to its position in active
Table 1. Crystal Structures of the Kinase Domain of Abl
Crystal Structure
(Resolution)
Distinct Conformations
in Asymmetric Unit
DFG
Conformation
Helix aC/Glu
Conformation
Ligand Abl Wild-Type
or Mutant
PDB ID: 1OPJ (1.75 A˚) Molecule A (imatinib-bound) DFG-Asp Out aC-Glu In Imatinib Wild-type
Structure 1PDB ID: 2G1T (1.8 A˚) Molecule B (Src-like inactive) DFG-Asp In aC-Glu Out ATP–peptide conjugate 1 Wild-type
Structure 2 PDB ID: 2G2I (3.1 A˚) Molecule C (active) DFG-Asp In aC-Glu In ATP–peptide conjugate 1 H396P
Structure 3 PDB ID: 2G2F (2.7 A˚) Molecule D (inactive) DFG-Asp Out aC-Glu In ATP–peptide conjugate 2 H396P
Molecule E (intermediate) DFG-Asp Out aC-Glu Out ATP–peptide conjugate 2
Structure 4 PDB ID: 2G2H(2.0 A˚) Molecule F (inactive) DFG-Asp Out aC-Glu In PD166326 H396P
Molecule G (intermediate) DFG-Asp Out aC-Glu Out PD166326
DOI: 10.1371/journal.pbio.0040144.t001
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structures. The coordinated Mg2þ ion is also displaced and
bound between the a and b phosphates of ATP, and not
between the b and c phosphates (Figure 2B).
The region of the activation loop immediately C-terminal
to the DFG motif in molecule B forms a single turn of a 310
helix that packs against helix aC, forming an extensive
hydrophobic interface that stabilizes the aC-Glu Out con-
formation (Figure 2A; the activation loop is colored blue).
The DFG motif and the leucine residue immediately follow-
ing a canonical type II b turn [31], with Asp 381 occupying the
first position in the turn.
Abl molecule B closely resembles the inactive Src kinases
(Figure 2C). Alignment of Abl molecule B (residues 246 to
500, excluding residues 381 to 402 in the activation loop, see
below) with the corresponding regions of c-Src [7] and Hck
[8] yields root mean square (r.m.s.) deviations of 1.17 A˚ and
0.99 A˚, respectively, for Ca atoms. The major difference
between the structures of Src kinases and the structure of Abl
molecule B concerns the central region of the activation loop,
residues 389 to 402 in Abl (Figure 2C). In Abl, this region of
the activation loop adopts a conformation in which Tyr 393 is
pointed outward and appears to be presented for phosphor-
ylation by another kinase molecule.
A Speculation Regarding DFG Flips and Src-Like Inactive
Conformations, Based on the Ramachandran Diagram
The structure of molecule B indicates, for the first time, that
a Src-like inactive conformation is accessible to Abl (Figure
1B). This led us to ask whether there is a particular functional
significance for this conformation. In addition to a possible
autoinhibitory role as a stable form of the unphosphorylated
kinase domain, certain features of molecule B suggested to us
that a Src-like inactive conformation may function as an
intermediate conformation that facilitates the DFG flip. The
DFG motif is located at the base of the activation loop, in an
environment that is tightly packed in the active conformation.
A salient feature in both inactive Src and Abl molecule B (Src-
like inactive) is the presence of a sizable internal cavity around
the DFG motif that is created by the outward rotation of helix
aC [8]. This cavity is an enlargement of the ATP-binding
pocket, and its presence results in the environment of the
DFG motif being considerably less hindered sterically in the
Src-like inactive conformation than in the active conforma-
tion of protein kinases.
The backbone torsion angles involved in the DFG-Asp In/
Out transition are shown in Figure 2D. The torsion angles of
Asp 381 are very similar in the active (u¼48.08, w¼83.28) and
Src-like inactive conformations of Abl (u ¼ 49.68, w ¼ 36.48),
but distinct in the DFG-flipped conformation (u¼152.98, w
¼ 98.68). A Ramachandran diagram based on free energy
calculations on the isolated alanine dipeptide in aqueous
solution [32] shows that there are three low-energy paths in
backbone torsion angle space for the u and w torsion angles
of Asp 381 by which the aspartate residue can begin the
transition from the active or the Src-like conformation
toward the DFG-flipped conformation (Figure 2E). The most
direct route in backbone torsion angle space for this
transition involves decreasing the value of u while increasing
the value of w (Path C in Figure 2E). Such a coupled set of
torsion angle changes immediately drives the side chain of
Phe 382 into the C-lobe and cannot be counteracted by
changes in any other downstream torsion angles. Path C
therefore seems unlikely.
The two other low-energy paths, A and B, when coupled to
backbone rotations in Phe 382, are nearly equivalent in terms
of the movements of the side chains of Asp 381 and Phe 382
(this point is discussed further below). The initial steps along
Path A involve increasing the values of both u and w for Asp
381. The consequence of aþ308 rotation in both u and w for
Asp 381 in the structure of active Abl is illustrated in Figure
2F. Asp 381 moves down into the base of the ATP-binding site
and away from Lys 271, while Phe 382 moves up toward the
ATP-binding pocket, but does not enter it. Further move-
ment of Phe 382 appears to be blocked by side chains of helix
aC. If the same set of rotations is made in the context of Abl
molecule B (Src-like inactive), there is a striking difference.
The side chain of Phe 382 now enters the enlarged ATP-
binding cavity, and there is no obvious steric block to its
continued movement (Figure 2F).
This simple analysis suggests that structural features in the
Src-like inactive structure might facilitate the DFG flip, but a
particularly difficult question concerns the mechanism by
which the charged side chain of Asp 381 is stabilized as it
moves away from the highly polar environment of the ATP-
binding site. To gain more insight into this issue we turned to
molecular dynamics simulations of the DFG flip mechanism.
Targeted Molecular Dynamics Simulations of the DFG-Asp
In/Out Transition
The DFG-Asp In/Out transition is unlikely to occur
spontaneously in conventional molecular dynamics simula-
tions, which are currently restricted to the nanosecond
timescale for proteins the size of the Abl kinase domain
[33]. We therefore employed a version of the targeted
molecular dynamics simulation method [34], in which an
external force is applied to a selected portion of the protein
structure in order to drive a desired conformational
transition [35]. Here we used targeted molecular dynamics
to drive the conformation of the DFG motif from the active
conformation (DFG-Asp In) or the Src-like conformation
(DFG-Asp In) to the imatinib-bound conformation (DFG-Asp
Out). These simulations explore the transitions denoted 1
and 2 in Figure 1D.
The targeted molecular dynamics method drives a selected
portion of the simulated structure to be at a desired r.m.s.
distance from a target structure. The entire kinase domain as
well as the surrounding box of water molecules is allowed to
move in response to the driving force, which is applied
directly to only a portion of the simulated system. The
desired r.m.s. distance is decreased gradually during the
simulation so that, eventually, the simulated structure is
driven to be close to the target structure. The restraint
energy, Erestraint, is given by
Erestraint ¼ kN2 ðD DTÞ
2 ð1Þ
where k is force constant, N is the number of atoms included
in the restraint, D is the current mass-weighted r.m.s. distance
of the restrained region from the target, and DT is the desired
value of the r.m.s. distance.
For a fully solvated simulation system containing the kinase
domain we are able to obtain a 0.2-ns trajectory in about a day
using two Intel 3.06 GHz Xeon processors. We carried out
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multiple trajectories of this length (86 in total) to gauge the
effects of parameters such as the force constant and the atoms
in the restraint set. A few simulations (12 in total) extended for
longer times (1–4.5 ns). The essential features of the
transitions are the same in the long and the short trajectories.
Simulations were carried out using restraint sets ranging
from the entire kinase domain to only four residues,
including the Asp 381 and the Phe 382 residues of the DFG
motif (379VADF382). The manner in which the DFG flip occurs
is essentially the same in every trajectory (Figure 3), and most
of our analysis focuses on simulations in which the restraint
force was applied to the four-residue segment 379VADF382.
More details regarding the force constants and the restraint
sets are given in Protocol S1.
Because of the strong driving forces necessitated by the
short simulation times (see Protocol S1 and Figure S2), these
simulations cannot be used to obtain meaningful estimates as
to whether the DFG flip occurs at a faster rate in transition 1
(active to DFG flipped) or transition 2 (Src-like inactive to
DFG flipped, Figure 1D). Such estimates would require
calculation of the free energy barriers to the transitions
[36–38] with proper consideration of the role of ATP/
ADPMg2þ (not included in most of the present simulations;
see Protocol S1). This is a time-consuming calculation and is
left for future investigations. Instead, the highly consistent
pathways generated by the simulations are analyzed in terms
of the intermediate structures that are present in the
trajectories. Coordinates sampled from representative tra-
jectories are available for download as Datasets S1 and S2.
Phe 382 Uses the Enlarged ATP-Binding Pocket in the Src-
Like Inactive Conformation during Simulated DFG
Transitions
The simulations reveal two different transition pathways
between the Src-like inactive and the imatinib-bound
structures (Figure 3C) that correspond to the two low-energy
paths A and B for Asp 381 backbone torsion angles in the
Ramachandran diagram (Figure 2E). Both paths show the side
chain of Phe 382 passing through the enlarged ATP-binding
cavity found in the Src-like inactive conformation (Figure 3B);
this is in accord with the analysis based on the Ramachandran
diagram, described earlier. The differences between the two
paths, A and B, are restricted to the direction of the
movement of the backbone carbonyl group of Asp 381 (see
Figure S3 for an illustration of a path B transition).
Analogous simulations starting with the active structure of
the Abl kinase domain (transition 1 in Figure 1D) show that
the active structure can also accommodate the DFG flip, but
apparently less well than the Src-like structure. The presence
of the salt bridge between Glu 286 and Lys 271 impedes the
flip of the phenylalanine residue in the DFG motif, as a
significant clash occurs between the oxygen atoms of the Glu
side chain and the carbonyl group of Phe 382 in the
approximately 30 simulations started from the active con-
formation (Figure 3D).
Features in the Src-Like Inactive Structure That Stabilize
Asp 381 during Simulated DFG Flips
All of the simulations initiated from the Src-like inactive
structure (transition 2 in Figure 1D) reveal a similar
mechanism for how the negative charge of Asp 381 can be
coordinated during the transition. The aspartate side chain
passes underneath the polypeptide backbone of the DFG
motif and forms an extensive hydrogen-bonding network
with the backbone amide groups of the next three residues
(Figure 3A). This type of interaction between an Asp side
chain and the backbone is commonly seen in crystal
structures and is referred to as an Asx turn [39]. When this
interaction occurs immediately N-terminal to a-helices, the
arrangement of the backbone NH groups helps to stabilize
the negative charge of the Asp side chain. The 310 helix
immediately following the DFG motif in the molecule B has a
corresponding stabilizing interaction with the aspartate of
the DFG motif during the flip. This 310 helix in the activation
loop is a characteristic feature of the Src-like inactive
conformation, and it has now been observed in four different
protein kinase families: Abl, Src, epidermal growth factor
receptor, and CDK2 (Figure 4A).
Asp 381 is also stabilized during the transition by an
interaction with Arg 386, a conserved ligand of the
phosphorylated tyrosine residue in activated kinases [11,40].
The side chain of Arg 386, which is part of the 310 helix, forms
a salt bridge to the flipped-out Glu 286 in molecule B, an
interaction that is also seen in the structures of inactive c-Src
and Hck [7,8]. Arg 386 in Abl molecule B is also oriented by
an amino–aromatic interaction [41] with Phe 359 in the
catalytic loop and a hydrogen bond to a backbone carbonyl
(Figure 4B). This orientation of Arg 386 allows it to capture
Asp 381 in many of the simulations as it emerges from
beneath the backbone of the activation loop (Figure 3A and
Figure 4C and 4D).
There is a qualitative difference between intermediate
structures formed in simulations initiated with the Src-like
structure (transition 2, Figure 1D) and the active structure
(transition 1, Figure 1D). In simulations of both transitions,
the first structural changes to occur are the breakage of the
ionic interactions between Asp 381 and Lys 271 and the
entrance of Phe 382 into the nucleotide-binding pocket,
which happen in a concerted manner. In simulations initiated
from the Src-like inactive structure, an intermediate is
formed in which Asp 381 is coordinated by the backbone
amide groups of the next three residues. In the simulations
starting from the active structure, Asp 381 is either not
coordinated when the ionic interaction breaks, or is
coordinated by only one amide group.
The simulations also reveal a potential role for the type II b
turn adopted by the 381DFGL384 residues of the DFG motif
Figure 2. Molecule B Closely Resembles the Structure of the Inactive Src Kinases
(A) The kinase domain of Abl (molecule B) is shown as a cartoon with the bisubstrate analog inhibitor depicted as a stick model.
(B) Structure of the ATP–peptide conjugate at the active site.
(C) Comparison between molecule B (left) and the structure of a Src-family kinase (right).
(D) Backbone torsion angles of Asp 381 of the DFG motif.
(E) The backbone of Asp 381 can start to move from DFG-In to the DFG-Out conformations by three paths in torsion angle space [32].
(F) Illustration of rotations about u(Asp 381) and w(Asp 381) in the Src-like inactive versus the active structures of Abl.
DOI: 10.1371/journal.pbio.0040144.g002
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that is a characteristic feature of the Src-like inactive
structure but not the active structure. This type II b turn
aligns the backbone amide groups of residues Gly 383 and
Leu 384 so that they are pointing down toward the C-lobe of
the kinase domain, allowing for coordination of the aspartate
as it undergoes the transition. A hydrogen bond to a
backbone carbonyl in the C-lobe anchors the backbone
amide of Gly 383, such that a type II b turn is favored over a
type I b turn in the Src-like inactive conformation. The
backbone conformation following the DFG motif in the Src-
like inactive structure can also be classified as a potential
anion-binding site [42].
The glycine of the DFG motif is essentially invariant among
protein kinases. A role for this residue in the active
conformation is suggested by the structure of the serine
threonine kinase protein kinase A, in which the presence of
glycine in the DFG motif appears to be necessary for proper
coordination of Mg2þATP [43]. Interestingly, type II b turns
display a strong preference for glycine at the third position
[31], suggesting that the Src-like inactive conformation also
imposes a requirement for glycine in the DFG motif.
Additional Structures of Abl Suggest How Helix aC Might
Transition to the aC-Glu Out Conformation
The simulations do not address the question of how Glu
286, in helix aC, moves out of the active site to adopt its
solvent-exposed position in the Src-like inactive structure.
This is an important question because such a transition
involves breaking the ion pair between Glu 286 and Lys 271
and is unlikely to happen unless compensating electrostatic
interactions are provided (Table S2). Two crystal structures of
Abl reported in this work (molecules E and G) advance our
understanding of this question.
Molecules E and G were obtained from the same crystal
form of Abl and are very similar, except for the presence of
either the ATP-peptide analog (molecule E) or the kinase
inhibitor PD166326 (molecule G). In these structures, the
kinase adopts a conformation intermediate between aC-Glu
In and aC-Glu Out: while helix aC is not rotated out of the
active site of the kinase, a rotation of the side chain of Glu
286 has occurred, resulting in the breakage of the Glu 286–
Lys 271 salt bridge. This interaction is replaced by an ion pair
between Glu 286 and Arg 362 in the catalytic loop, part of a
conserved His-Arg-Asp (HRD) motif (Figure 5A). The
existence of a salt bridge between Glu 286 and the HRD
arginine (Arg 362) in molecules E and G would be expected to
offset the energetic cost of breaking the Glu 286–Lys 271 salt
bridge. Once the salt bridge is broken, the interface between
helix aC and the rest of the N-lobe of the kinase is exclusively
hydrophobic. The helix could then rotate relative to the b-
sheet of the N-lobe. We propose that this rotation could
occur without breaking the stabilizing interaction between
Glu 286 and Arg 362 (Figure 5B).
In support of the idea that Arg 362 in the HRD motif might
provide electrostatic stabilization as Glu 286 moves out of the
active site, the same ion pair corresponding to Glu 286 and
the HRD Arg 362 is seen in the earliest reported structures of
the inactive Src kinases, Src and Hck [44,45]. In these
structures, helix aC has rotated out while maintaining the
Glu-HRD Arg ion pair. In the crystal structure of GCN2, the
same ion pair is formed in the context of an aC-Glu Out
conformation [23]. Thus this ion pair is compatible with both
the aC-Glu In and aC-Glu Out conformations. A schematic of
the proposed aC-Glu In/Out transition pathway is shown in
Figure 5B.
Potential Relevance for a Src-Like Inactive Structure in
Imatinib Resistance
Clinical resistance to imatinib therapy is a growing
problem in the treatment of chronic myeloid leukemia [46].
Mutations that confer resistance to imatinib have been
mapped using patient-derived samples and by using in vitro
screens [47,48]. Surprisingly, only a minority of the imatinib
resistance mutations result in direct blockage of the drug-
binding site. A larger class of mutations appear to act by
destabilizing the specific inactive conformation of Abl to
which imatinib binds [47]. A third class of mutations cannot
be rationalized easily in this manner; many of these occur in
regions of the structure that have essentially identical
conformation in the imatinib-bound and active conforma-
tions, or are solvent-exposed. It is unclear how mutations at
such sites preferentially destabilize the imatinib-bound
conformation, while allowing the kinase to retain catalytic
activity.
Notably, a striking number of resistance mutations map to
the interface between helix aC and the N-lobe of the kinase
(Figure 6A). This interface is preserved between the active
and imatinib-bound structures, but in the Src-like inactive
structure (molecule B) the altered orientation of helix aC and
the presence of the 310 helix in the activation loop result in a
much larger interface. Mapping the location of the resistance
mutations onto molecule B shows that almost every residue at
the enlarged aC/N-lobe interface can confer imatinib
resistance when mutated (Figure 6A).
Several of the resistance mutations play a particularly
important structural role in the Src-like conformation of Abl,
but are of less obvious importance in the imatinib-bound or
active conformations. For example, the side chain of Asp 276
makes two strong hydrogen bonds with backbone amide
groups in the activation loop immediately following the helical
turn in molecule B (Figure 6B, right). These interactions help
anchor the activation loop in the Src-like conformation and
Figure 3. Targeted Molecular Dynamics Simulations Suggest a Path for DFG Flipping
(A) Coordination of Asp 381 during the DFG flip, shown in stereo, starting from the Src-like structure and following transition path A in backbone torsion
angle space (see Figure 2E). The coordination of Asp 381 is almost identical for transition path B, except that the carbonyl of Asp 381 flips in the other
direction (see Figure S3).
(B) The side chain of Phe 382 passing through a hydrophobic pocket in the Src-like inactive molecule B.
(C) The paths of Asp 381 and Phe 382 in backbone torsion angle space for two trajectories starting with the Src-like inactive structure. Shown in red are
the torsion angles seen in the first quarter of a TMD time series, in green, the second quarter of the time series, in blue, the third quarter, and in purple,
the last quarter.
(D) Unfavorable interactions between the backbone carbonyl of Phe 382 and the carboxylate group of Glu 286 during TMD simulations starting from
the active structure, where the Glu 286-Lys 271 salt bridge is present.
DOI: 10.1371/journal.pbio.0040144.g003
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would be disrupted by the patient-derived resistancemutation
identified at this position (D276G) [49] as well as by the D276V
mutation isolated in the in vitro screen [48]. The importance
of similar interactions in the maintenance of the inactive form
of c-Src has been demonstrated previously [50]. In contrast,
Asp 276 is solvent-exposed in the Abl:imatinib complex
(Figure 6B, left) and in the active structure.
Two more examples are the hydrophobic residues Leu 387
and Met 278, which are completely buried in the extended
interface between helix aC, the N-lobe, and the helical turn in
the activation loop in the Src-like inactive structure
(molecule B; Figure 6C and 6D, right). Mutations of Leu 387
have been isolated in the patient-resistance studies (L387F/
M), while a mutation of Met 278 (M278L) was identified in the
in vitro screen. In the imatinib complex, both Leu 387 and
Met 278 are largely solvent-exposed (Figure 6C and 6D, left).
Other mutations are discussed in Protocol S1 and Figure S4.
Activation-loop phosphorylation is expected to stabilize
Abl in the active conformation, and imatinib binds to
phosphorylated Abl with greatly reduced affinity. Although
BCR–Abl is phosphorylated constitutively in cells, tyrosine
phosphatases ensure that a dynamic interconversion exists
between the phosphorylated and unphosphorylated forms of
the protein (Figure 1D [51]), and the continual formation of
unphosphorylated BCR–Abl through this interconversion is
critical for the efficacy of imatinib [4,28,51]. Because of the
competition between autophosphorylation and imatinib
binding, mutations that perturb the balance between the
different conformational states of Abl could have a dramatic
effect on the efficacy of imatinib.
Conclusions
The central result of this paper is the discovery that the
kinase domain of Abl can readily adopt a conformation that
resembles closely that of the inactive Src kinases. This is a
surprise, because all previously seen conformations of the
inactive forms of the Abl kinase domain have in common a
flipped DFG motif (DFG-Asp Out/aC-Glu In), whereas the
DFG motif is not flipped in the structures of the inactive Src
kinases. The high-affinity binding of imatinib to Abl and its
other targets requires a flipped DFG motif. Although c-Src
binds to imatinib with low affinity, other Src kinases, such as
Lck, bind to imatinib with greater affinity [52,53]. This
suggests that just as Abl can adopt a Src-like inactive
structure, the Src kinases can, with varying ease, adopt the
inactive conformation that is characteristic of Abl.
Our results link, for the first time, Src-like inactive and
DFG-flipped inactive conformations in the same protein
molecule. Because of the location of the DFG motif deep
within the active-site cleft of the kinase, the flipping of the
DFG motif is unlikely to occur without significant rearrange-
ments in the rest of the kinase domain. We hypothesize, based
Figure 4. The Helical Turn following the DFG motif in Src-Like Inactive Structures
(A) The helical turn in the activation loop of molecule B that immediately follows the DFG motif is a characteristic feature of the Src-like conformation
and is conserved in four different kinase families.
(B and C) The side chain of Arg 386, presented by the helical turn, forms a hydrogen bond to a backbone carbonyl of Ile 360, a salt bridge with Glu 286,
and an amino–aromatic interaction with Phe 359 that positions it for interacting with Asp 381 during the DFG flip.
(D) An intermediate structure during one of the TMD simulations, showing the capture of Asp 381 by Arg 386.
DOI: 10.1371/journal.pbio.0040144.g004
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on analysis of the structures in combination with targeted
molecular dynamics simulations, that the DFG flip might be
facilitated by adoption of the Src-like inactive structure.
When helix aC is moved out of the active site, the DFG motif
is freed from the steric hindrance imposed by the salt bridge
between Glu 286 and Lys 271. The side chain of Phe 382 can
then move through the sizable hydrophobic pocket created
by the outward displacement of helix aC. Throughout the
flip, the negative charge of Asp 381 is stabilized by the
backbone amide groups of the activation loop and inter-
action with Arg 386.
The discovery that Abl adopts a Src-like inactive con-
formation suggests a mechanism by which one class of
mutations in the kinase domain of Abl might allow the
protein to escape inhibition by imatinib. These mutations
map to regions of the kinase domain that undergo major
structural changes when the kinase adopts the Src-like
inactive conformation. These mutations might affect kinase
activity at equilibrium if the Src-like inactive conformation
represents a major population of the inactive Abl molecules
in solution. Such effects may be difficult to detect in the
isolated kinase domain of Abl, in which conformational
transitions do not appear to be rate-limiting when compared
to substrate binding and release or the chemical step, as
evidenced by the fact that phosphorylation does not increase
the activity of the isolated kinase domain [4]. A previous
study of resistance mutations using only the kinase domain
of Abl has shown only subtle effects for several resistance
mutations [54]. It may be important to study the attributes of
resistance in the context of BCR–Abl or large constructs of
c-Abl.
The DFG motif is conserved across almost every member of
the eukaryotic protein kinase superfamily [2]. In addition, the
surrounding residues that interact with the DFG motif are
also highly conserved [2]. This makes it challenging to devise
experiments that involve mutagenesis of the DFG motif or
residues in its immediate environment in such a way that the
results could be interpreted without ambiguity. Character-
ization of the imatinib resistance mutations may provide one
experimental route by which to investigate the effect of
mutations on the conformational changes in the kinase
domain of Abl. Ultimately, however, NMR measurements of
structure and dynamics, combined with computer simula-
tions, are likely to be required to establish the relevance of
the Src-like inactive structure for the regulation of Abl. In
this regard, it is encouraging that preliminary NMR analyses
of dynamics in kinase domains are yielding promising results
[55,56].
Figure 5. The Structure of Abl in an Intermediate Conformation Suggests a Path for the Transition between the Active and Src-Like Conformations
(A) The intermediate structure of Abl (molecule E) is shown, with helix aC shown in blue, the activation loop in red, and the catalytic loop containing
Arg 362 in orange.
(B) The proposed pathway by which Abl makes the transition to the Src-like conformation.
DOI: 10.1371/journal.pbio.0040144.g005
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Materials and Methods
Bacterial expression of Abl. The kinase domain of human c-Abl
(residues 229–512) was coexpressed with the tyrosine phosphatase
YopH in bacteria according to a published protocol [27,57]. The
protein was purified by affinity and anion exchange chromatography,
and size-exclusion chromatography showed that the protein was
monomeric and free of aggregates. The H396P mutation was made
using the QuikChange site-directed mutagenesis kit (Stratagene, La
Jolla, California, United States) and purified as above. Proteins were
concentrated to 10 mg/ml in gel filtration buffer (50 mM Tris-HCl
[pH 8.0], 100 mM NaCl, 10% glycerol, and 0.5 mM DTT), snap-frozen
in liquid nitrogen, and stored at 80 8C.
Synthesis of the bisubstrate analog inhibitors. The peptide
portions of the substrate analogs were assembled by solid-phase
peptide synthesis using Fmoc chemistry, performed as reported
previously [25,30], with minor modifications. The tyrosine of the
substrate was replaced by azidophenylalanine during each synthesis.
The sequence used for analog 1 was the ‘‘Cantley Src peptide’’ (NH2-
AEEEIYGEFEAKK-COOH), and the peptide sequence of analog 2 was
the optimal Abl substrate (NH2-EAIYAAPFAKK-COOH) [58]. With
the peptide still bound on the resin, the azidophenylalanine was
reduced to aminophenylalanine by addition of a large excess of
tributylphosphine in dimethylformamide. Bromoacetic acid was
mixed with diisopropylcarbodiimide in a 2:1 molar ratio in dichloro-
methane. After stirring for 10 min the solvent was removed and the
symmetric anhydride dissolved in dimethylformamide before addi-
tion to the resin. After cleavage from the resin the bromoacetylated
peptide was precipitated in cold ether and lyophilized. The dried
peptides were purified by reversed-phase HPLC (water:acetonitrile
gradient) and confirmed by mass spectrometry. Coupling of the
purified peptide to ATPcS was performed overnight with a small
excess of ATPcS in 1 M ammonium acetate (pH 6.5). The substrate
analogs were purified by gel filtration, dried, and stored at 80 8C.
The structure of the compounds was verified by electrospray
ionization mass spectrometry.
Crystallography and refinement of Abl. The substrate analogs were
dissolved in buffer (100 mM Tris-HCl [pH 8.0] and 10 mM MgCl2) and
added to the purified kinase domain of wild-type or H396P Abl in gel
filtration buffer (50 mM Tris-HCl, 100 mM NaCl, 10% glycerol, 0.5
mM DTT). Crystals were grown in hanging drops with 10 mg/ml Abl
kinase and 1 mM inhibitor. The crystals were cryoprotected in well
solution plus 30% glycerol and frozen in liquid nitrogen. Diffraction
data were collected at beamlines 8.2.2 and 12.3.1 of the Advanced
Light Source.
Data were processed using Denzo and Scalepack [59] and
molecular replacement was performed using the Phaser program
[60] of the ccp4 suite. Refinement of molecular replacement solutions
was performed using CNS [61], and atomic models were built with the
program O [62].
The crystals of the wild-type protein (Table 1, structure 1) grew in
0.2 M sodium acetate, 100 mM sodium cacodylate (pH 6.5), and 25%
PEG 8,000 in space group P21 but had all unit cell angles equal to 908
(a¼ 62.6 A˚, b¼ 78.4 A˚, c¼ 141.6 A˚). Given the orthorhombic unit cell
and the monoclinic space group, diffraction data were susceptible to
partial merohedral twinning. By screening X-ray data from many
crystals we obtained a dataset to 1.8 A˚ resolution with negligible
twinning. Refinement of the molecular model, obtained by molecular
replacement using the Abl:PD173955 complex (PDB code 1M52),
against these data produced satisfactory statistics (R-value of 21.9%
and Rfree ¼ 24.4%), and deconvolution of twinned intensities during
refinement was deemed unnecessary. The crystals contain four
essentially identical molecules in the asymmetric unit (molecule B
is a representative structure).
Figure 6. Molecule B Helps Explain Mutations in the Kinase Domain of Abl That Confer Resistance to Imatinib
(A) The side chains of residues implicated in imatinib resistance in the Azam et al. study [48] are shown in blue in the context of molecule B. A large
number of these mutations cluster in the interface between helix aC, the N-lobe, and the helical turn in the activation loop.
(B–D) For three of these mutations we have shown the surface for all atoms within 6 A˚ of the mutated residue in the context of different structures. The
Abl:imatinib complex is in green and the Src-like structure (molecule B) in yellow-orange. (B) Asp 276. (C) Leu 387. (D) Met 278.
DOI: 10.1371/journal.pbio.0040144.g006
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Crystals of the H396P mutant form of Abl in complex with
substrate analog 1 (Table 1, structure 2) grew in 2 M sodium malonate
in space group P41212 (a ¼ 88.5 A˚, b ¼ 88.5 A˚, c ¼ 235.6 A˚) but
diffracted X-rays weakly. A molecular replacement solution was
obtained with the Abl:PD173955 complex (PDB code 1M52) from
which the activation loop had been deleted. Refinement of the model
using group B factors to 3.1 A˚ resolution yielded interpretable
electron density maps that clearly showed the presence of the
inhibitor and the conformation of the activation loop. Some limited
building was performed to fix regions of the structure clearly affected
by the presence of the drug in the molecular replacement search
model. The structure was refined to an R-value of 24.9% (Rfree ¼
30.8%). The structure is very similar to the structure of Abl H396P
bound to the small molecule inhibitor VX-680 [27].
Crystals of the kinase domain of Abl H396P in complex with
bisubstrate inhibitor 2 (Table 1, structure 3) were obtained in 0.1 M
Bis-Tris (pH 5.5) and 25% PEG 3350 in space group P21212 (a ¼
105.7 A˚, b ¼ 133.3 A˚, c ¼ 56.6 A˚) and diffracted X-rays to 2.7 A˚. The
structure was solved by molecular replacement, as above, and
refined to an R-value of 23.2% (Rfree ¼ 28.6%). The same crystal
form (P21212, a¼ 104.4 A˚, b¼ 131.5 A˚, c¼ 56.5 A˚) was also obtained
by cocrystallizing the kinase domain of Abl H396P with PD166326
(in 100% DMSO). These crystals grew in 0.1M citric acid (pH 3.5)
and 25% PEG 3350. The crystals diffracted to higher resolution (2.0
A˚), and the structure was refined to an R-value of 19.3% (Rfree ¼
21.3%; Table 1, structure 4). The two models were refined
independently but are almost identical. Significant differences are
localized to the P-loop, the conformation of which depends on
which ligand is bound to the kinase. These two P-loop conforma-
tions are the same as those previously visualized for complexes of
Abl with PD166326 and for the structures of nucleotide complexes
of protein kinases.
Molecular dynamics. Molecular dynamics trajectories were calcu-
lated using either the high-resolution structure of active, unphos-
phorylated Abl kinase domain [27], after the H396P mutation was
mutated back to His, using the program O, or Src-like inactive Abl
kinase domain (molecule B), as the starting points and the imatinib-
bound structure, molecule A [9], as the target. All molecular dynamics
simulations were performed with the TIP3P explicit water model [63]
and with Kþ counterions. The initial structures were immersed in a
truncated octahedral cell of water molecules and counterions were
added using the LEAP module of AMBER, version 7, with the parm96
force field [64–66]. The water extended at least 8 A˚ past the surface of
the protein molecule. The SANDER module of AMBER was used to
calculate the trajectories at constant temperature and pressure,
SHAKE was used to constrain bonds to hydrogen [67], and the
particle mesh Ewald summation method was used to calculate
electrostatic interactions [68]. The system was initially equilibrated
for 150 ps, and positional restraints were applied for the first 50 ps as
described earlier [69]. In order to generate independent trajectories,
different random-number seeds were used for the initial assignment
of velocities, and this resulted in equilibrated structures with r.m.s.
deviations of at least 1 A˚ from each other for all Ca atoms. Targeted
molecular dynamics trajectories were calculated using SANDER [70].
DT (see Equation 1 in the main text) was decremented continuously
throughout the simulations, starting at the difference between the
two crystal structures and ending at zero.
Eighty-six trajectories were calculated using different force
constants ranging from 0.01 kcal mol1 A˚2 to 100 kcal mol1 A˚2.
The trajectories spanned 200–225 ps when starting from the Src-like
inactive structure and 200 ps when starting from the active structure,
since the active structure was closer to the target in terms of r.m.s.
deviation. Ten approximately 1-ns and two approximately 4-ns
trajectories were also calculated. The entire protein was driven
toward the target in some trajectories, whereas in some the restraint
comprised the 25 residues in the activation loop. In most trajectories
only 4–5 residues in the vicinity of the DFG motif were restrained.
CHARMM was used to analyze the data [71]. In the simulations
involving restraints on the whole kinase domain or the entire
activation loop, the restraint set was used for the alignment of the
simulation structure on the target structure. The alignment needed
to be modified for the simulations involving only five or four residues,
so as to provide a frame of reference for the DFG flip. In these
simulations, the ten residues N-terminal to the DFG motif were also
included in the alignments but not in the restraint potential.
Equilibrium molecular dynamics simulations were set up as described
above except that no targeting force was applied. These were used for
comparison with the targeted molecular dynamics simulations and
lasted at least 5 ns.
Supporting Information
Dataset S1. Targeted Molecular Dynamics Trajectory following
Transition 1 in Figure 1D
This dataset includes coordinates of all the atoms in the simulation
sampled every several picoseconds and an example script for viewing
the trajectory using PyMOL.
Found at DOI: 10.1371/journal.pbio.0040144.sd001 (1.7 MB ZIP).
Dataset S2. Targeted Molecular Dynamics Trajectory following
Transition 2 in Figure 1D
This dataset includes coordinates of all the atoms in the simulation
sampled every several picoseconds and an example script for viewing
the trajectory using PyMOL.
Found at DOI: 10.1371/journal.pbio.0040144.sd002 (1.4 MB ZIP).
Figure S1. Sequence-Specific Interactions between the ATP–Peptide
Conjugates and the Kinase Domain of Abl
(A) The structure of the peptide–ATP conjugates. (B) Interactions
between the ATP–peptide conjugate with the optimal peptide
sequence and Abl molecule E. (C) Interactions between the ATP–
peptide conjugate with the suboptimal peptide sequence and Abl
molecule B.
Found at DOI: 10.1371/journal.pbio.0040144.sg001 (7.6 MB PDF).
Figure S2. Choice of Restraint Set and Force Constant for TMD
(A) When only the residues 379VADF382 are restrained, the deviation
in the N-lobe is minimal. Gray: molecule B, starting structure; Yellow-
orange: simulation final structure.
(B) Restraint force (pN), and r.m.s. distance of the restraint from the
target (A˚), plotted versus time (picoseconds) for two low-force
constant (K¼ 0.15 kcal mol1 A˚2) simulations starting with the active
structure.
Found at DOI: 10.1371/journal.pbio.0040144.sg002 (2 MB PDF).
Figure S3. Targeted Molecular Dynamics Simulations Propose a Path
for DFG Flipping
(A) Coordination of Asp 381 during the DFG flip, starting from the
Src-like inactive structure (molecule B) and following transition path
B in backbone torsion angle space. The coordination of Asp 381 is
almost identical for transition path A, except that the carbonyl of Asp
381 flips in the other direction.
(B) The side chain of Phe 382 passing through a hydrophobic pocket
in the Src-like molecule for transition path B.
(C) The paths of Asp 381 and Phe 382 in backbone torsion angle space
for two trajectories.
Found at DOI: 10.1371/journal.pbio.0040144.sg003 (17 MB PDF).
Figure S4.Molecule B Helps Explain Mutations in the Kinase Domain
of Abl That Confer Resistance to Imatinib
For two of these mutations we have shown the surface for all atoms
within 6 A˚ of the mutated residue in the context of different
structures. The active structure is shown in pink, the Abl:imatinib
complex in green, and the Src-like structure (molecule B) in yellow-
orange. (A) Phe 359. (B) Tyr 253.
Found at DOI: 10.1371/journal.pbio.0040144.sg004 (7.7 MB PDF).
Protocol S1. Basis for the Specificity of the Kinase Domain of Abl for
Peptide Substrates
Found at DOI: 10.1371/journal.pbio.0040144.sd003 (49 KB DOC).
Table S1. Crystallographic Data and Refinement
Found at DOI: 10.1371/journal.pbio.0040144.st001 (40 KB DOC).
Table S2. Hydrogen Bond Distances between Key Residues
Found at DOI: 10.1371/journal.pbio.0040144.st002 (26 KB DOC).
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